Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Early doxycycline use may raise pregnancy loss risk
Investigators found higher pregnancy loss rates compared with alternative antibiotics for respiratory infections, although findings among patients with acne differed across databases.
Clinical Scorecard: Early doxycycline use may raise pregnancy loss risk
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: Early doxycycline use may raise pregnancy loss risk
Key Mechanisms
Mechanisms or clinical associations described in the source article.
Target Population
Patients aged 12 to 55 years with first-trimester prescriptions for doxycycline or comparator antibiotics, analyzed in separate cohorts treated for respiratory tract infections or acne.
Care Setting
Care setting described in the source article.
Key Highlights
In respiratory tract infection cohorts, doxycycline was associated with higher adjusted relative risks of pregnancy loss than amoxicillin in both claims databases.
Comparisons with macrolides also showed higher adjusted relative risks of pregnancy loss among doxycycline-exposed patients with respiratory tract infections.
For acne, an association was observed in MarketScan but not in the Medicaid analysis.
The retrospective observational design cannot establish causation; residual confounding and exposure misclassification remain possible.
The study did not evaluate congenital malformations, and stillbirth-specific findings were inconclusive because of small event numbers.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
The source provides no specific monitoring recommendations.
Risks
Patient & Prescribing Data
For respiratory tract infections, pregnancy loss occurred in 32% versus 20% of doxycycline- versus amoxicillin-exposed pregnancies in MarketScan, and 27% versus 19% in Medicaid. Compared with macrolides, rates were 32% versus 22% in MarketScan and 27% versus 20% in Medicaid. For acne, rates were 27% versus 18% in MarketScan and about 20% in both groups in Medicaid.
Clinical Best Practices
Weigh the potential benefits and risks of doxycycline when considering treatment during early pregnancy, as advised by the study authors.
Interpret the reported associations in light of the observational design and the possibility of residual confounding.
Do not infer congenital-malformation risk from this study; congenital malformations were not evaluated.
